Syros Pharmaceuticals Inc. (NASDAQ:SYRS)‘s stock had its “outperform” rating reiterated by investment analysts at Wedbush in a report issued on Monday. They currently have a $18.00 price target on the stock. Wedbush’s target price would suggest a potential upside of 35.14% from the stock’s current price.

A number of other equities analysts have also weighed in on the stock. Zacks Investment Research raised shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, October 20th. Piper Jaffray Cos. reissued a “buy” rating and issued a $20.00 price objective on shares of Syros Pharmaceuticals in a research report on Thursday, September 22nd. HC Wainwright reissued a “hold” rating and issued a $10.00 price objective on shares of Syros Pharmaceuticals in a research report on Friday, September 9th. Cowen and Company assumed coverage on shares of Syros Pharmaceuticals in a research report on Monday, July 25th. They issued an “outperform” rating for the company. Finally, JMP Securities assumed coverage on shares of Syros Pharmaceuticals in a research report on Monday, July 25th. They issued an “outperform” rating and a $22.00 price objective for the company. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Syros Pharmaceuticals currently has an average rating of “Buy” and an average price target of $17.50.

Analyst Recommendations for Syros Pharmaceuticals (NASDAQ:SYRS)

Syros Pharmaceuticals (NASDAQ:SYRS) opened at 13.32 on Monday. The stock’s market cap is $311.34 million. The firm has a 50-day moving average of $13.60 and a 200 day moving average of $13.05. Syros Pharmaceuticals has a 12 month low of $8.16 and a 12 month high of $21.50.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings data on Monday, November 14th. The company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.54) by $0.11. Analysts anticipate that Syros Pharmaceuticals will post ($2.98) EPS for the current year.

A number of institutional investors have recently modified their holdings of the company. California State Teachers Retirement System bought a new position in shares of Syros Pharmaceuticals during the third quarter valued at approximately $137,000. Spark Investment Management LLC bought a new position in shares of Syros Pharmaceuticals during the third quarter valued at approximately $160,000. Hamilton Lane Advisors LLC bought a new position in shares of Syros Pharmaceuticals during the third quarter valued at approximately $193,000. Morgan Stanley bought a new position in shares of Syros Pharmaceuticals during the third quarter valued at approximately $469,000. Finally, AWM Investment Company Inc. bought a new position in shares of Syros Pharmaceuticals during the third quarter valued at approximately $660,000. 54.63% of the stock is owned by hedge funds and other institutional investors.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing treatments for cancer and immune-mediated diseases. The Company’s gene control platform focuses on identifying gene control targets linked to genomically defined patient populations, and drugging gene control targets.

5 Day Chart for NASDAQ:SYRS

Receive News & Stock Ratings for Syros Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.